Nektar Therapeutics Q3 loss widens on higher R&D and G&A expenses
Nektar Therapeutics Q3 loss widens on higher R&D and G&A expenses Overview Biotechnology company rep
Related stories
Volkswagen Plans Up to 100,000 Job Cuts by 2030
Volkswagen plans to cut up to 100,000 jobs worldwide by 2030 as it restructures operations. The headline says four German plants are at risk.
M impact | EQUITY | Nov 15, 2026, 03:31 AM UTC
US Air Travel Disruptions to Persist Until Late Sunday, FAA Head Says
The FAA head said disruptions to US air travel are expected to persist until late Sunday. The wire reports airlines are canceling flights.
M impact | EQUITY | Nov 15, 2026, 02:42 AM UTC
Air Travel Disruptions Expected to Persist Into Sunday, Officials Say
Officials say thousands of flights are affected as air travel issues are expected to continue well into Sunday.
M impact | EQUITY | Nov 14, 2026, 11:56 PM UTC
SpaceX Starship Returns to Landing Pad After 22-Hour Orbital Voyage
SpaceX’s Starship returned from a 22-hour voyage in orbit and was caught by mechanical arms at the Texas launch tower, a first for the spacecraft.
M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC
SpaceX Starship Returns to Landing Pad From Orbit
SpaceX’s Starship returned to its landing pad from orbit, completing a test of reusable rockets.
M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC
Air Travel Disruptions to Persist Into Sunday, Officials Say
Officials say thousands of flights have been affected, with air travel issues expected to persist well into Sunday.
M impact | EQUITY | Nov 14, 2026, 09:39 PM UTC